The Role of Glasses in Aseptic Production: A Detail Often Ignored - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Role of Glasses in Aseptic Production: A Detail Often Ignored

Pharmaceutical Technology

Figure 2: Sterilization graphic to wave quadrant that enables us to verify the D value to one sterilization´s specific temperature.
An autoclave known as a BIER-vessel must be used to evaluate the D value. The most important characteristic of this autoclave is its ability to produce a sterilization graphic to wave quadrant (see Figure 2), which allowed the verification of the D value to one sterilization cycle's specific temperature.


Facial adherence and transmittance checks. The facial adherence did not change after 30 steam sterilization cycles. The goggles maintained their adherence without any shape modification caused by steam.

Even if the transmittance variations are minimal and can be attributed to measurement uncertainty, we verified that the transmission increased slightly with the increase in the number of sterilization cycles. The 84.1% transmittance value of the lenses increased to about 2 points after 20 cycles. After 30 cycles, transmittance decreased slightly under the starting value because of the appearance of superficial sediment and slight blurring of the lenses' surface. In any case, we concluded that after 30 sterilization cycles, the transmittance does not vary significantly. In fact, for all tested samples, transmittance was more than 75%, which linked with a check of the unchanging lenses' surface transparency, guaranteed that high visibility was maintained.

Particle-release check. Particle-release results for glasses subjected to repeated sterilization cycles were analyzed separately for the visor (lenses and support) and the elastic strip.

Figure 3: Percentage of particles in the 0.2–1.0 mm range released by the frames during the autoclave cycles.
Check of the visor particle release. The particles' cumulative calculation, in the range between 0.2 and 1.0 μm, shows a proportional linear growth of the total particles compared with the autoclave cycles to which the glasses were submitted (see Figure 3).

The contribution is given by the particles with diameters smaller than 0.2 µm that reach values greater than 90% of the total after 10 sterilization cycles, with exponential growth. The 0.4, 0.6, 0.8, and 1.0-μm diameter particles decrease with analogous progression.

The glasses' particle release, in the considered dimensional range, may be attributed to pollution of the sample obtained after repeated autoclave cycles. The polymer reticule of the glasses could favor the inclusion of the 0.2-μm dimension particles that are in the water used for the autoclave feeding and used as washing water before the analysis. The high temperatures to which the glasses were subjected favor plastic material expansion and the introduction of particles with smaller dimensions.

The 0.4–1.0-μm particles that quickly decrease to values lower than 10% of the total after 10 sterilization cycles were present on the sample's surface and not inside the polymer, because they would not be able to imbed themselves during the autoclave cycles and were washed away from the glasses' surface.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here